According to the health ministry India, shortage of manpower and disruption in supply of raw materials to the pharmaceuticals sector has affected the production capacity of leading anti-TB drug manufacturers in the country.
“Such a situation will worsen the treatment of the TB patients in the country,” Union health secretary Preeti Sudan said in a letter dated April 17 to the empowered group, which has been constituted to facilitate supply chain and logistics management amid the Covid-19 outbreak.
According to Sudan, suppliers have communicated that TB drug supplies will be delayed because of force majeure on account of Covid-19, limited material of API for production, and issues with manpower and transportation facilities...
Full text at GMPnews.Net